ClinicalTrials.gg
RecruitingNCT06282055TIMESUpdated Dec 3, 2025

Trajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes

An observational study in Diabetes Mellitus, Type 1, sponsored by DCB Research AG. Recruiting at 1 site in Switzerland. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by DCB Research AG · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.

Planned enrollment
5th of 18
350 · median 73
Started
2025
with 3 others
Observational
18 of 70
4 open now
Registered
63rd of 70
by date
Lead sponsor
3 of 70
DCB Research AG

Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 5th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 63rd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, or all of them as a file.
02

Study summary

Standardized longitudinal data collection of diabetes management relevant factors in women with T1D (insulin requirements, glucose variability, nutritional information, and menstrual cycle information) to identify categories of cycle trajectories.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Menstrual cycle
  • Trajectories
  • Women
  • Insulin sensitivity
  • Glycaemia
  • Insulin need
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with menstrual cycles living with Type 1 Diabetes who are using a hybrid closed-loop system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female sex
  • Between 18 and 40 years at inclusion
  • Menarche at least one year prior to study inclusion
  • Regular menstrual cycle (at least one menstrual cycle in the last 40 days)
  • Average menstrual cycle length between 21 and 38 days
  • Difference in length between consecutive menstrual cycles of at most 7 days
  • Living with type 1 diabetes or latent diabetes in adults (LADA) for at least one year
  • Actively using an AID system for their diabetes management at least six months prior to study inclusion

Exclusion criteria

Exclusion criteria:

  • Regular hormonal intake (e.g. ), except: insulin, stable thyroid substitution, and hormonal
  • Pregnancy until two months postpartum (ongoing or planned)
  • Current breastfeeding (including pumping), as well as two months following complete cessation of breastfeeding and pumping
  • Known Polycystic Ovary Syndrome (PCOS)
  • Intake of glucocorticoid medication, agents affecting gastric emptying, oral anti-diabetic agents (Metformin) or SGLT-2 inhibitors or GLP-1-analogs
  • Individuals with work patterns involving frequent shifts between night and day work (e.g., alternating night and day shifts on a weekly or similar basis).
  • Participation in an interventional study within two months preceding and during the present study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Patient registry
No

Groups and cohorts

  • Women with T1D

    Women living with T1D who are willing to share their diabetes management and menstrual cycle data.

    Other: No intervention

Interventions

  • OtherNo intervention

    Observational prospective longitudinal data collection

06

What researchers measure

Primary outcomes

  1. Identify clusters in trajectories across the menstrual cycle

    1. Insulin sensitivity across the menstrual cycle/menstrual cycle phases (see Table 1 for definitions relevant to the clinical endpoints). 2. Glycemia measures across the menstrual cycle/menstrual cycle phases: * Percentage in Time In Range (TIR), Rime In Tight Range (TITR), Time Below Range (TBR), Time Above Range (TAR), Coefficient of Variation (CV) * Mean glucose and mean fasted glucose * High and Low Blood Glucose Index (HBGI and LBGI) and Glucose Management Indicator (GMI) 3. Insulin administration measures across the menstrual cycle/menstrual cycle phases: * Basal and bolus insulin dosage * Total daily dose (TDD) * Basal/bolus ratio

    Time frame: 6 months

Secondary outcomes

  1. To quantify and classify the techniques used for manual insulin adjustments, comparing their utilization and effectiveness.

    2\. Manual Insulin Adjustment Techniques: * Frequency and classification (e.g., timing, magnitude) of manual insulin adjustments. * Impact of adjustment techniques on glycemic outcomes.

    Time frame: 6 months

  2. To quantify differences in clusters in insulin sensitivity, glycemic metrics and insulin administration across different phases of the menstrual cycle

    Identification and characterization of distinct clusters in glycemic metrics, insulin administration and insulin sensitivity representing unique patterns across distinct menstrual cycle phases (early follicular phase, late follicular phase, peri-ovulation, early luteal, mid luteal and late luteal phase)

    Time frame: 6 months

  3. To identify predictive factors that correlate individual participants and menstrual cycles with specific insulin sensitivity and clinical endpoints.

    Predictive Factors: o Identification of demographic, clinical, or physiological predictors (e.g., premenstrual cycle syndrome (PMS) score or age group) that significantly correlate with primary outcomes.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We plan to share the data but haven't specified the details yet.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 21 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 28, 2024
StartActual
Nov 20, 2025
Primary completionEst.
Sep 15, 2027
CompletionEst.
Sep 15, 2027
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06282055
Lead sponsor
DCB Research AG
Collaborators
The Danish Diabetes Association, Heart and Diabetes Center North Rhine-Westphalia, University of Bristol, Emory University
Responsible party
Sponsor
First posted
Feb 28, 2024
Start date
Nov 20, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Dec 3, 2025

Study contacts

Stefanie Hossmann, MSc
Contact
stefanie.hossmann@dcberne.com
+41794217376
Martina Rothenbühler, PhD
Contact
martina.rothenbuehler@dcberne.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion